Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mirati Therapeutics Inc.

www.mirati.com

Latest From Mirati Therapeutics Inc.

Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend

Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.

Financing Business Strategies

Finance Watch: Expect A Busy First Half For 2020 IPOs

Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.

Financing Business Strategies

Merck Joins KRAS Stampede In Deal With Otsuka Affiliates

Merck & Co. is paying $50m up front to combine preclinical KRAS-target cancer compound pipelines with Astex and Taiho, both affiliates of Japan’s Otsuka. The two biotechs could realize up to $2.5bn in earnouts under the collaboration.

Deals Research and Development Strategies

Amgen Joins China Oncology Market Race With $2.7bn BeiGene Stake

As China embraces novel new drugs, oncology is quickly becoming the biggest opportunity for pharma to drive growth in this market. Amgen is the latest to jump on board through the purchase of a significant stake in BeiGene.

China Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • MethylGene Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mirati Therapeutics Inc.
  • Senior Management
  • Charles M Baum, MD, PhD, Pres. & CEO
    Jamie Donadio, SVP, CFO
    Isan Chen, MD, Chief Medical & Dev. Officer
    James Christensen, PhD, EVP, CSO
    Chris LeMasters, CBO
    Daniel R Faga, EVP, COO
    Benjamin J Hickey, EVP, Chief Commercial Officer
  • Contact Info
  • Mirati Therapeutics Inc.
    Phone: (858) 332-3410
    9393 Towne Centre Dr.
    Ste. 200
    San Diego, CA 92121
    USA
UsernamePublicRestriction

Register